ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2018
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- The risk of organ-based comorbidities in psoriasis: a systematic review and meta-analysis.Anais brasileiros de dermatologiaPooled it
- Trial
- Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).The British journal of dermatology · 2023Trial
- Trial
- Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.The British journal of dermatology · 2021Trial
- Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis.Advances in therapy · 2026Review
- Concomitant psoriasis may be associated with a more severe disease course in inflammatory bowel disease: a retrospective cohort study.Scientific reports · 2026Article
- Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.The Journal of clinical and aesthetic dermatology · 2026Review
- Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study.Dermatology and therapy · 2026Article
- Lights and Shadows of Nutrient-Driven Keratinocyte Inflammation in Psoriasis.International journal of molecular sciences · 2025Review
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Effects of combined treatment withFood science and biotechnology · 2025Article
- Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.ACR open rheumatology · 2024Article
- Residual metabolic burden in young psoriasis patients successfully treated with biologics.Archives of dermatological research · 2024Article
- Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection.Cureus · 2024Review
- Guselkumab - In Psoriasis and Beyond.Dermatology practical & conceptual · 2024Review
- Article
- Successful guselkumab treatment of a refractory psoriasis patient with Graves' disease: a case report.The Journal of international medical research · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis have advanced considerably in recent years, and in parallel, so too have the available treatment options. Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic therapies, starting with tumour necrosis factor-alpha (TNF-α) inhibitors and later, agents targeting interleukin (IL)-12/23 and IL-17. The most recent evidence suggests that IL-23 might be an even more potent target for the effective treatment of psoriasis and other autoimmune inflammatory disorders. This review will describe recent developments leading to the current understanding of the key role of IL-23 as a 'master regulator' of autoimmune inflammation and the clinical evidence for agents that specifically target this modulator in the context of treating psoriasis, spondyloarthropathy and inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.